Perspective Therapeutics (CATX) 10-K 9 Sep 16 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2016	Sep. 01, 2016	Dec. 31, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	IsoRay, Inc.
Entity Central Index Key	728,387
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 51,303,319
Trading Symbol	ISR
Entity Common Stock, Shares Outstanding		55,010,619

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Current assets:
Cash and cash equivalents	$ 10,139,026	$ 5,226,740
Certificates of deposit (Note 3)	2,247,111	9,362,574
Accounts receivable, net of allowance for doubtful accounts of $30,000 and $30,000, respectively	604,867	1,049,041
Inventory	334,395	403,955
Other receivables	108	19,615
Prepaid expenses and other current assets	303,734	263,597
Total current assets	13,629,241	16,325,522
Property and equipment, net	576,692	574,840
Certificates of deposit, non-current (Note 3)	2,973,348	5,106,775
Restricted cash	181,420	181,262
Inventory, non-current	590,616	569,854
Other assets, net of accumulated amortization	150,533	245,031
Total assets	18,101,850	23,003,284
Current liabilities:
Accounts payable and accrued expenses	610,585	498,253
Accrued protocol expense	122,156	124,131
Accrued radioactive waste disposal	177,000	129,500
Accrued payroll and related taxes	72,220	212,795
Accrued vacation	111,356	127,515
Total current liabilities	1,093,317	1,092,194
Long-term liabilities:
Warrant derivative liability	27,000	181,000
Asset retirement obligation	580,480	947,849
Total liabilities	1,700,797	2,221,043
Commitments and contingencies (Note 15)
Shareholders' equity:
Common stock, $.001 par value; 192,998,329 shares authorized; 55,010,619 and 54,967,559 shares issued and outstanding	55,010	54,968
Treasury stock, at cost, 0 and 13,200 shares, respectively	0	(8,390)
Additional paid-in capital	82,788,299	82,467,111
Accumulated deficit	(66,442,315)	(61,731,507)
Total shareholders' equity	16,401,053	20,782,241
Total liabilities and shareholders' equity	18,101,850	23,003,284
Series A Preferred Stock [Member]
Shareholders' equity:
Preferred Stock, Value, Issued	0	0
Series B Preferred Stock [Member]
Shareholders' equity:
Preferred Stock, Value, Issued	59	59
Series C Preferred Stock [Member]
Shareholders' equity:
Preferred Stock, Value, Issued	0	0
Series D Preferred Stock [Member]
Shareholders' equity:
Preferred Stock, Value, Issued	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Allowance for Doubtful Accounts Receivable, Current	$ 30,000	$ 30,000
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	7,001,671	7,001,671
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	192,998,329	192,998,329
Common Stock, Shares, Issued	55,010,619	54,967,559
Common Stock, Shares, Outstanding	55,010,619	54,967,559
Treasury Stock, Shares	0	13,200
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	59,065	59,065
Preferred Stock, Shares Outstanding	59,065	59,065
Series C Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series D Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1,671	1,671
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Product sales, net	$ 4,769,276	$ 4,606,539	$ 4,219,158
Cost of product sales	4,640,122	4,439,146	4,415,629
Gross profit (loss)	129,154	167,393	(196,471)
Operating expenses:
Research and development	528,049	614,771	668,803
Sales and marketing	1,352,735	1,488,456	1,234,725
General and administrative	3,786,657	2,400,353	2,488,219
Change in estimate of asset retirment obligation (Note 9)	(456,284)	0	0
Total operating expenses	5,211,157	4,503,580	4,391,747
Operating loss	(5,082,003)	(4,336,187)	(4,588,218)
Non-operating income (expense):
Interest income	218,145	282,745	12,113
Change in fair value of warrant derivative liability	154,000	374,605	(1,382,134)
Financing and interest expense	(950)	(2,214)	(883)
Non-operating income (expense), net	371,195	655,136	(1,370,904)
Net loss	(4,710,808)	(3,681,051)	(5,959,122)
Preferred stock deemed dividends	0	0	(726,378)
Preferred stock dividends	(10,632)	(10,632)	(10,632)
Net loss applicable to common shareholders	$ (4,721,440)	$ (3,691,683)	$ (6,696,132)
Basic and diluted loss per share (in dollar per share)	$ (0.09)	$ (0.07)	$ (0.16)
Weighted average shares used in computing net loss per share:
Basic and diluted (in shares)	55,014,922	54,882,350	42,675,158

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' Equity - USD ($)	Total	Preferred Stock [Member]Series B Preferred Stock [Member]	Preferred Stock [Member]Series D Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Jun. 30, 2013	$ 5,366,246	$ 59	$ 0	$ 34,618	$ (8,390)	$ 57,431,293	$ (52,091,334)
Balance (shares) at Jun. 30, 2013		59,065	0	34,618,517	13,200
Issuance of preferred stock pursuant to underwritten pubic offering, net	1,478,703		$ 2			1,478,701
Issuance of preferred stock pursuant to underwritten pubic offering, net, shares			1,670
Issuance of common stock pursuant to underwritten pubic offering, net	1,800,589			$ 3,801		1,796,788
Issuance of common stock pursuant to underwritten pubic offering, net, shares				3,800,985
Conversion of Series D preferred stock to common stock	0		$ (2)	$ 3,121		(3,119)
Conversion of Series D preferred stock to common stock, shares			(1,670)	3,121,480
Issuance of common stock pursuant to exercise of warrants, net	7,012,941			$ 7,166		7,005,775
Issuance of common stock pursuant to exercise of warrants, net, shares				7,165,443
Issuance of common stock pursuant to exercise of options	$ 266,314			$ 351		265,963
Issuance of common stock pursuant to exercise of options, shares	350,983			350,983
Issuance of common stock pursuant to registered pubic offering, net	$ 13,814,742			$ 5,645		13,809,097
Issuance of common stock pursuant to registered pubic offering, net, shares				5,644,300
Retirement of treasury stock					$ 0
Payment of dividend to Preferred shareholders	(10,632)					(10,632)
Share-based compensation	185,987					185,987
Net loss	(5,959,122)	$ 0	$ 0	$ 0	0	0	(5,959,122)
Balance at Jun. 30, 2014	23,955,768	$ 59	$ 0	$ 54,702	$ (8,390)	81,959,853	(58,050,456)
Balance (shares) at Jun. 30, 2014		59,065	0	54,701,708	13,200
Issuance of common stock pursuant to exercise of warrants, net	99,644			$ 59		99,585
Issuance of common stock pursuant to exercise of warrants, net, shares				58,947
Issuance of common stock pursuant to exercise of options	$ 213,248			$ 207		213,041
Issuance of common stock pursuant to exercise of options, shares	206,904			206,904
Retirement of treasury stock					$ 0
Payment of dividend to Preferred shareholders	$ (10,632)					(10,632)
Share-based compensation	205,264					205,264
Net loss	(3,681,051)	$ 0	$ 0	$ 0	0	0	(3,681,051)
Balance at Jun. 30, 2015	20,782,241	$ 59	$ 0	$ 54,968	$ (8,390)	82,467,111	(61,731,507)
Balance (shares) at Jun. 30, 2015		59,065	0	54,967,559	13,200
Issuance of common stock pursuant to exercise of options	$ 49,940			$ 42		49,898
Issuance of common stock pursuant to exercise of options, shares	56,260			56,260
Retirement of treasury stock	$ 0				$ 8,390	(8,390)
Retirement of treasury stock, shares				(13,200)	(13,200)
Payment of dividend to Preferred shareholders	(10,632)					(10,632)
Share-based compensation	290,312					290,312
Net loss	(4,710,808)	$ 0	$ 0	$ 0	$ 0	0	(4,710,808)
Balance at Jun. 30, 2016	$ 16,401,053	$ 59	$ 0	$ 55,010	$ 0	$ 82,788,299	$ (66,442,315)
Balance (shares) at Jun. 30, 2016		59,065	0	55,010,619	0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,710,808)	$ (3,681,051)	$ (5,959,122)
Adjustments to reconcile net loss to net cash used by operating activities:
Allowance for doubtful accounts	0	(8,607)	(13,992)
Depreciation expense	470,851	576,380	685,396
Loss on equipment disposals	6,512	0	0
Writeoff of inventory associated with discontinued product	72,200	0	0
Amortization of other assets	107,037	36,987	30,189
Change in fair value of warrant derivative liability	(154,000)	(374,605)	1,382,134
Accretion of asset retirement obligation	88,915	81,289	74,318
Change in estimate of asset retirment obligation	(456,284)	0	0
Share-based compensation	290,312	205,264	185,987
Changes in operating assets and liabilities:
Accounts receivable, gross	444,174	(127,385)	24,723
Inventory	(23,402)	(144,314)	45,834
Other receivables	19,507	33,467	(41,580)
Prepaid expenses and other current assets	(40,137)	(57,550)	(3,167)
Accounts payable and accrued expenses	112,332	(76,602)	142,289
Accrued protocol expense	(1,975)	43,698	55,128
Accrued radioactive waste disposal	47,500	(12,092)	41,592
Accrued payroll and related taxes	(140,575)	(23,487)	108,863
Accrued vacation	(16,159)	6,750	13,187
Net cash used by operating activities	(3,884,000)	(3,521,858)	(3,228,221)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for property and equipment	(479,215)	(133,305)	(19,029)
Additions to licenses and other assets	(12,539)	(17,942)	(17,758)
Proceeds from maturity of certificates of deposit	15,491,539	15,873,376	0
Purchases of certificates of deposit	(6,133,027)	(10,143,741)	(10,002,912)
Purchases of certificates of deposit, non-current	(109,622)	(4,794,674)	(5,401,398)
Change in restricted cash	(158)	(54)	(59)
Net cash provided (used) by investing activities	8,756,978	783,660	(15,441,156)
CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid	(10,632)	(10,632)	(10,632)
Proceeds from sales of preferred stock, pursuant to underwritten offering, net	0	0	1,478,703
Proceeds from sales of common stock, pursuant to underwritten offering, net	0	0	1,800,589
Proceeds from sales of common stock, pursuant to registered direct offering, net	0	0	13,814,742
Proceeds from sales of common stock, pursuant to exercise of warrants, net	0	82,249	6,099,807
Proceeds from sales of common stock, pursuant to exercise of options	49,940	213,248	266,314
Net cash provided by financing activities	39,308	284,865	23,449,523
Net increase (decrease) in cash and cash equivalents	4,912,286	(2,453,333)	4,780,146
Cash and cash equivalents, beginning of fiscal year	5,226,740	7,680,073	2,899,927
CASH AND CASH EQUIVALENTS, END OF FISCAL YEAR	10,139,026	5,226,740	7,680,073
Supplemental discolosures of cash flow information:
Cash paid for interest	950	2,214	748
Non-cash investing and financing activities:
Retirement of treasury stock	0
Preferred stock deemed dividends	0	0	(726,378)
Reclassification of derivative warrant liability to equity upon exercise	0	17,395	(913,134)
Reclassification of convertible preferred stock to common stock upon conversion	0	0	(1,478,703)
Treasury Stock [Member]
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	0	0	0
Non-cash investing and financing activities:
Retirement of treasury stock	$ (8,390)	$ 0	$ 0

Organization

Organization	12 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. Organization IsoRay, Inc. was incorporated in Minnesota in 1983. On July 28, 2005, IsoRay Medical, Inc. (Medical) became a wholly-owned subsidiary of IsoRay, Inc. (formerly known as Century Park Pictures Corporation) pursuant to a merger. Medical was formed under Delaware law on June 15, 2004 and on October 1, 2004 acquired two affiliated predecessor companies which began operations in 1998. Medical, a Delaware corporation, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. Medical is headquartered in Richland, Washington. IsoRay International LLC (International), a Washington limited liability company, was formed on November 27, 2007 and is a wholly-owned subsidiary of the IsoRay, Inc. International has entered into various international distribution agreements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Summary of Significant Accounting Policies The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP), and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (collectively the Company). All significant inter-company transactions and balances have been eliminated in consolidation. The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are held in various financial institutions in the United States. Certificates of deposit with original maturities greater than three months and remaining maturities less than one year are classified as "Certificates of deposit" and included in current assets. Certificates of deposit with remaining maturities greater than one year are classified as ”Certificates of deposit, non-current” and are included in noncurrent assets. Accounts receivable are stated at the amount that management of the Company expects to collect from outstanding balances. Management provides for probable uncollectible amounts through an allowance for doubtful accounts. Additions to the allowance for doubtful accounts are based on management's judgment, considering historical experience with write-offs, collections and current credit conditions. Balances which remain outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts and a credit to the applicable accounts receivable. Payments received subsequent to the time that an account is written off are treated as bad debt recoveries. Inventory is reported at the lower of cost or market. Cost of raw materials is determined using the weighted average method. Cost of work in process and finished goods is computed using standard cost, which approximates actual cost, on a first-in, first-out basis. The cost of materials and production costs contained in inventory that are not useable due to the passage of time, and resulting loss of bio-effectiveness, are written off to cost of product sales at the time it is determined that the product is no longer useable. Materials contained in inventory that are components of a discontinued product are classified as a non-recurring charge to general and administrative expense. Fixed assets are capitalized and carried at cost less accumulated depreciation. Normal maintenance and repairs are charged to expense as incurred. When any assets are sold or otherwise disposed of, the cost and accumulated depreciation are reversed with any resulting gain or loss being recognized on the consolidated statement of operations. Production equipment 3 7 Office equipment 2 5 Furniture and fixtures 2 5 Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Management periodically reviews the net carrying value of all of its long-lived assets on an asset by asset basis. An impairment loss is recognized if the carrying amount of a defined asset group is not recoverable and exceeds its fair value. Although management has made its best estimate of the factors that affect the carrying value based on current conditions, it is reasonably possible that changes could occur which could adversely affect management's estimate of net cash flows expected to be generated from its assets that could result in an impairment adjustment. Prepaid expenses and other assets, which include deferred charges, patents and licenses, are stated at cost, less accumulated amortization. Amortization of patents is computed using the straight-line method over the estimated economic useful lives of the assets. Licenses include costs related to licenses pertaining to the use of technology or operational licenses. These licenses are recorded at stated cost, less accumulated amortization. Amortization of licenses is computed using the straight-line method over the estimated economic useful lives of the assets. The Company periodically reviews the carrying values of licenses and evaluates the recorded basis for any impairment. Any impairment is recognized when the expected future operating cash flows to be derived from the licenses are less than their carrying value. The Company periodically reviews the carrying values of patents and any related impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. The estimated fair value of the future retirement costs of the Company's leased assets and the costs for the decontamination and reclamation of equipment located within the footprint leased asset are recorded as a liability on a discounted basis when a contractual obligation exists; an equivalent amount is capitalized to property and equipment. The initial recorded obligation is discounted using the Company's credit-adjusted risk-free rate and is reviewed periodically for changes in the estimated future costs underlying the obligation. The Company amortizes the initial amount capitalized to property and equipment and recognizes accretion expense in connection with the discounted liability over the estimated remaining useful life of the leased assets. The Company discloses the fair value of financial instruments, both assets and liabilities, recognized and not recognized in the balance sheet, for which it is practicable to estimate the fair value. The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than a forced liquidation sale. At June 30, 2016 and 2015, the carrying value of financial instruments which include certificates of deposit and restricted cash, approximated fair value. ASC Topic 820, Fair Value Measurements At June 30, 2016 and 2015, there were no assets or liabilities measured at fair-value on a recurring basis which were measured using Level 3 inputs. The Company had a single liability, the derivative warrant liability, which was measured at fair value on a recurring basis using Level 2 inputs during the years ended June 30, 2016, 2015 and 2014. Certain assets and liabilities are measured at fair value on a non-recurring basis; that is, the instruments are not measured at fair value on an ongoing basis, but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). With the exception of the asset retirement obligation (Note 9), the Company had no assets or liabilities measured at fair value on a nonrecurring basis during the three years ended June 30, 2016. The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Fair value at June 30, 2016 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 10,139,026 $ 10,139,026 $ - $ - Warrant derivative liability 27,000 - 27,000 - Fair value at June 30, 2015 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,226,740 $ 5,226,740 $ - $ - Warrant derivative liability 181,000 - 181,000 - The Company’s cash and cash equivalent instruments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company’s warrant derivative liability is valued using the Black-Scholes option pricing model which requires a variety of inputs as described in Note 11. Such instruments are typically included in Level 2. For the warrant derivative liabilities which are measured at fair value on a recurring basis, the Company uses the Black-Scholes valuation model as described in Note 11. Revenue Recognition The Company recognizes revenue related to product sales when (i) persuasive evidence of an arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. The Company recognizes revenue once the product has been shipped to the customer. Prepayments, if any, received from customers prior to the time that products are shipped are recorded as deferred revenue. In these cases, when the related products are shipped, the amount recorded as deferred revenue is then recognized as revenue. The Company accrues for sales returns and other allowances at the time of shipment. Shipping and handling costs include charges associated with delivery of goods from the Company's facilities to its customers and are reflected in cost of product sales. Shipping and handling costs paid to the Company by its customers are classified as product sales. The Company measures and recognizes expense for all share-based payments at fair value. The Company uses the Black-Scholes option valuation model to estimate fair value for all stock options on the date of grant. For stock options that vest over time, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. Research and development costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year recognized. For the Years Ended June 30, 2016 2015 2014 Advertising and marketing costs expensed (including tradeshows) $ 157,347 $ 151,197 $ 114,313 At June 30, 2016 2015 Prepaid marketing expenses deferred until event occurs $ 12,222 $ 9,600 The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. Estimating probable losses requires analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. Currently, the Company does not believe any probable legal proceedings or claims will have a material adverse effect on its financial position or results of operations. However, if actual or estimated probable future losses exceed the Company's recorded liability for such claims, it would record additional charges as other expense during the period in which the actual loss or change in estimate occurred. Income taxes are accounted for under the liability method. Under this method, the Company provides deferred income taxes for temporary differences that will result in taxable or deductible amounts in future years based on the reporting of certain costs in different periods for financial statement and income tax purposes. This method also requires the recognition of future tax benefits such as net operating loss carry-forwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment of the change. In the event that the Company is assessed penalties and or interest, penalties will be charged to other operating expense and interest will be charged to interest expense in the period that they are assessed. Basic earnings per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not include the impact of any potentially dilutive common stock equivalents, including preferred stock, common stock warrants or options that are potentially convertible into common stock, as those would be antidilutive due to the Company's net loss position. June 30, 2016 2015 2014 Preferred stock 59,065 59,065 59,065 Common stock warrants 230,087 385,800 444,747 Common stock options 2,925,059 2,418,282 2,314,422 Total potential dilutive securities 3,214,211 2,863,147 2,818,234 The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company's fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company's production facilities; inputs used in the calculation of expense related to share-based compensation including volatility, estimated lives and forfeiture rates of options granted; and the inputs to the Black-Scholes calculation to estimate the fair value of the derivative warrant liability and the related gain or loss. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, "Revenue from Contracts with Customers" (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, "Revenue Recognition". The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11: Inventory. The guidance requires an entity’s management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements. In November 2015, the FASB issued an ASU 2015-17 to simplify the balance sheet classification of deferred taxes. This update requires all deferred tax assets and liabilities to be reported as non-current in the consolidated balance sheets. This update will be effective as of the beginning of fiscal 2018. This update is not expected to have a material impact on the Company’s consolidated financial statements . In February 2016, the FASB issued ASU 2016-02 Leases (Subtopic 842), which will require lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases. The update is effective for annual and interim reporting periods beginning after December 15, 2018. We are currently evaluating the impact of the guidance on the Company’s consolidated financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Certificates of deposit

Certificates of deposit	12 Months Ended
	Jun. 30, 2016
Investments, All Other Investments [Abstract]
Cost-method Investments, Description [Text Block]	3. Certificates of deposit Certificate of Deposit Account Registry Service (CDARS) is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $ 250,000 Under 90 91 days to Six months to Greater days six months 1 year than 1 year CDARS, as of June 30, 2016 $ $ $ 2,247,111 $ 2,973,348 CDARS, as of June 30, 2015 $ 3,523,167 $ 500,064 $ 5,339,343 $ 5,106,775

Inventory

Inventory	12 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Inventory June 30, 2016 2015 Raw materials $ 155,178 $ 143,669 Work in process 160,936 204,760 Finished goods 18,281 55,526 Total inventory $ 334,395 $ 403,955 June 30, 2016 2015 Enriched barium, non-current $ 469,758 $ 469,758 Raw materials, non-current 120,858 100,096 Total inventory, non-current $ 590,616 $ 569,854 Inventory, non-current is raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not be consumed within an operating cycle and the enriched barium which will only be utilized if required to obtain volumes of isotope not able to be purchased from an existing source in the short or long-term. Management does not anticipate the need to utilize the enriched barium within the current operating cycle. As of March 2016, the Company discontinued the GliaSite® RTS product line resulting in a write-off of GliaSite® RTS related inventory totaling $ 72,200

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Jun. 30, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets [Text Block]	Prepaid Expenses and Other Current Assets June 30, 2016 2015 Prepaid insurance $ 46,108 $ 30,578 Other prepaid expenses 230,933 206,326 Other current assets 26,693 26,693 $ 303,734 $ 263,597

Property and Equipment

Property and Equipment	12 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Property & Equipment June 30, 2016 2015 Land $ 168,459 $ - Equipment 3,605,815 3,553,774 Leasehold improvements 4,129,977 4,129,977 Other 1 213,567 5,925 Property and equipment 8,117,818 7,689,676 Less accumulated depreciation (7,541,126) (7,114,836) Property and equipment, net $ 576,692 $ 574,840 1 – Plant and equipment, not placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet. Also included at June 30, 2016 are costs associated with advance planning and design work on the Company’s new production facility. Year Ended June 30, 2016 2015 2014 Depreciation expense $ 470,851 $ 576,380 $ 685,396 During fiscal 2016 the Company disposed of $51,071 in equipment. Of the $ 51,071 43,411 ® 7,660 10,359 59,723 6,512 ®

Restricted Cash

Restricted Cash	12 Months Ended
	Jun. 30, 2016
Cash and Cash Equivalents [Abstract]
Restricted Assets Disclosure [Text Block]	7. Restricted Cash The Washington Department of Health requires the Company to provide collateral for the decommissioning of its facility. To satisfy this requirement, the Company has a certificate of deposit (CD) with a balance $ 181,420

Other Assets, net

Other Assets, net	12 Months Ended
	Jun. 30, 2016
Other Assets [Abstract]
Other Assets Disclosure [Text Block]	8. Other Assets, net Other assets, net of accumulated amortization consisted of the following: June 30, 2016 2015 Deferred charges $ $ 46,541 Patents and trademarks, net of accumulated amortization of $215,497 and $134,559, respectively. 150,533 198,490 $ 150,533 $ 245,031 Year Ended June 30, 2016 2015 2014 Amortization expense on patents and trademarks $ 17,176 $ 25,226 $ 18,468 Change in estimate on patents and trademarks 1 63,762 - - Total amortization expense $ 80,938 $ 25,226 $ 18,468 Future amortization is expected to be as follows: FY2017 $ 17,612 FY2018 17,152 FY2019 16,905 FY2020 16,368 FY2021 16,368 Thereafter 66,128 $ 150,533 1 The change in estimate is the result of the review of information contained in the amortization assumptions which is based on new information resulted in a non-recurring change in the amortization expense.

Asset Retirement Obligation

Asset Retirement Obligation	12 Months Ended
	Jun. 30, 2016
Asset Retirement Obligation Disclosure [Abstract]
Asset Retirement Obligation Disclosure [Text Block]	Asset Retirement Obligation The Company has an asset retirement obligation (ARO) associated with the facility it currently leases. Year Ended June 30, 2016 2015 Beginning balance $ 947,849 $ 866,560 Accretion of discount 88,915 81,289 Gain on change in ARO estimate (456,284) 81,289 Ending balance $ 580,480 $ 947,849 The original facility lease was scheduled to expire in the fourth quarter 2016. Upon the end of the original lease term, the initial asset retirement estimate was fully accreted and the related ARO asset was fully amortized. During the year ended June 30, 2016, the Company extended the lease term an additional three years thus extending the time before asset retirement costs would be incurred. In addition, management determined that the estimated cost to retire the facility was less than the original estimate. Both of these factors resulted in a decrease in the ARO balance to a fair value of $ 580,480 456,284 650,000 1.1 5.1

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Share-Based Compensation The Company currently provides share-based compensation under three equity incentive plans approved by the Board of Directors: § Amended and Restated 2006 Director Stock Option Plan (2006 Director Plan); § 2014 Employee Stock Option Plan (2014 Employee Plan); and, § 2016 Equity Incentive Plan (2016 Incentive Plan). The 2006 Director Plan allows the Board of Directors to grant options to purchase up to 1,000,000 The 2014 Employee Plan allows the Board of Directors to grant options to purchase up to 2,000,000 The 2016 Equity Incentive Plan allows the Board of Directors to grant up to 4,000,000 Options granted under all of the plans have a ten year maximum term, an exercise price equal to at least the fair market value of the Company's common stock on the date of the grant, and varying vesting periods as determined by the Board. For stock options with graded vesting terms, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. The Company uses the Black-Scholes option valuation model because management believes the model is appropriate for the Company. However, management understands that because changes in the subjective input assumptions can materially affect the fair value estimate, this valuation model does not necessarily provide a reliable single measure of the fair value of its stock options. The risk-free interest rate is based on the U.S. treasury security rate with an equivalent term in effect as of the date of grant. The expected option lives, volatility, and forfeiture assumptions are based on historical data of the Company. For the Year Ended June 30, 2016 2015 2014 Weighted average fair value $0.60 $1.11 $1.28 Options issued 1,185,500 395,000 430,000 Exercise price $0.64 to $1.53 $1.47 $0.58 to $2.46 Expected term (in years) 1 to 5 4 to 5 4 to 5 Risk-free rate 0.51% to 1.62% 1.42% to 1.65% 1.48% to 1.85% Volatility 106% - 118% 107% 106% to 132% For the Year Ended June 30, 2016 2015 2014 Cost of product sales $ 70,842 $ 44,798 $ 17,818 Research and development expense 14,266 17,107 13,486 Sales and marketing expense 23,459 11,608 3,588 General and administrative expense 181,745 131,751 151,095 Total share-based compensation $ 290,312 $ 205,264 $ 185,987 The total value of the stock options awards is expensed ratably over the vesting period of the employees receiving the awards. As of June 30, 2016, total unrecognized compensation cost related to stock-based options and awards was $ 787,245 1.90 Options Outstanding Price (a) Life (b) Value (c) Balance at June 30, 2013 2,305,072 $ 1.83 4.93 $ 115,302 Granted (d) 380,000 1.81 Expired/Forfeited (19,667) 0.61 Exercised (350,983) 0.76 Balance at June 30, 2014 2,314,422 $ 2.00 4.69 $ 3,186,916 Granted (d) 395,000 1.41 Expired/Forfeited (84,236) 4.15 Exercised (206,904) 1.03 Balance at June 30, 2015 2,418,282 $ 1.91 4.71 $ 691,789 Granted (d) 1,185,500 .87 Expired (459,594) 3.48 Forfeited (162,869) 1.67 Exercised (56,260) .89 Balance at June 30, 2016 2,925,059 $ 1.21 6.93 $ 262,557 Vested and expected to vest at June 30, 2016 2,686,525 $ 1.20 6.88 $ 256,233 Exercisable at June 30, 2016 2,561,194 $ 1.18 6.73 $ 250,373 (a) Weighted average exercise price per share. (b) Weighted average remaining contractual life. (c) Aggregate intrinsic value. (d) All options granted had exercise prices equal to or greater than the ending closing market price of the Company's common stock on the grant date. The options were granted to employees and management by the Board of Directors and had vesting periods from immediate to five years. For the Year Ended June 30, 2016 2015 2014 Aggregate intrinsic value of options exercised $ 24,595 $ 306,620 $ 548,928 The Company's current policy is to issue new shares to satisfy option exercises.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Jun. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Shareholders’ Equity The authorized capital structure of the Company consists of $. 001 001 Preferred Stock The Company's Articles of Incorporation authorize 7,001,671 Series A At June 30, 2016 and 2015, there were 1,000,000 Series B Series B preferred shares are entitled to a cumulative 15 4 On December 10, 2015, the Board of Directors declared a dividend on the Series B Preferred Stock of all outstanding and cumulative dividends through December 31, 2014. The total dividends of $ 10,632 59,065 5,316 Series C At June 30, 2016 and 2015, there 1,000,000 Series D Established in August 2013, Series D preferred shares are entitled to dividends in the same form as dividends actually paid on shares of common stock. Additionally, the Company shall not pay any dividends on shares of common stock (other than dividends in the form of common stock) unless the holders of Series D Convertible Preferred Stock shall first receive dividends on shares of Series D Convertible Preferred Stock held by them (on an as-if-converted-to-common-stock-basis) in an amount equal to and in the same form as any such dividends (other than dividends in the form of common stock) to be paid on shares of common stock. Except as required by law, shares of Series D Convertible Preferred Stock shall not have the right to vote on any matter other than those set forth in the Certificate of Designation with the potential to specifically adversely affect the Series D Convertible Preferred Stock. Series D Convertible Preferred shares are convertible into shares of common stock at the rate of 1,869.15 9.99 In addition to the previously outstanding shares of common stock and Series B preferred stock, the Company had the following transactions that affected shareholders' equity during the fiscal years ended June 30, 2016, 2015 and 2014. Common and Preferred Stock Transactions Series D Preferred On August 29, 2013, the Company entered into an agreement to sell 3,800,985 0.816 1,525.23 0.535 1,000 0.72 1,869.15 726,378 3.7 3,279,292 During January 2014, the holder of the 1,670 1,670 3,121,480 38,419,502 41,540,982 Common Stock On March 21, 2014, the Company entered into a Securities Purchase Agreement with certain investors providing for the sale of a total of 5,644,300 14,675,180 2.60 13,814,742 Warrants Warrant derivative liability Based on the guidance contained in ASC 815 “Derivatives and Hedging”, management has concluded that the warrants issued in the 2011 offering should be classified as a derivative liability and has recorded a liability at fair value. For the Year Ended June 30, 2016 2015 2014 Change in fair value of the warrant derivative liability $ 154,000 $ 374,605 $ (1,382,134) A summary of the change in fair value of derivative warrant liability is as follows for the fiscal years presented. Quantity 1 Amount Balance at June 30, 2013 713,601 $ 104,000 Change in fair value 1,382,000 Warrants corrected 10,869 - Warrants redeemed in cashless exercise (22,472) - Warrants exercised (463,702) (913,000) Balance at June 30, 2014 238,296 $ 573,000 Change in fair value (374,605) Warrants exercised (13,209) (17,395) Balance at June 30, 2015 225,087 $ 181,000 Change in fair value (154,000) Balance at June 30, 2016 225,087 $ 27,000 Warrants Price (a) Balance at June 30, 2013 1,957,033 $ 1.38 Corrections 26,939 1.31 Warrants redeemed in cashless exercise (22,520) 0.96 Warrants exercised (7,165,443) 0.86 Warrants granted 5,648,738 0.72 Balance at June 30, 2014 444,747 1.43 Warrants exercised (58,947) 1.38 Balance at June 30, 2015 385,800 1.22 Warrants expired (155,713) 1.63 Balance at June 30, 2016 230,087 $ .94 (a) Weighted average exercise price per share. Number of Range of Expiration Warrants Exercise Prices 1 Date 199,437 0.94 October 2016 25,650 0.94 December 2016 5,000 0.98 June 2017 230,087 1 – Exercise prices have been rounded to the nearest whole cent.

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes Due to net losses, the Company did not record an income tax provision or benefit for the years ending June 30, 2016, 2015 and 2014. 35 As of June 30, 2016 2015 Fixed assets $ 610,000 $ 546,000 Share-based compensation 545,000 443,000 Reserves 13,000 11,000 Other accruals 119,000 85,000 Asset retirement obligation 203,000 332,000 Net operating loss carryforwards 19,110,000 17,508,000 Total deferred tax assets 20,600,000 18,925,000 Valuation allowance (20,600,000) (18,925,000) Total $ - $ - As management of the Company cannot determine that it is more likely than not that the Company will realize the benefit of the net deferred tax asset, a valuation allowance equal to 100 The Company has federal net operating loss carryforwards of approximately $ 55 For the year ended June 30, 2016 2015 2014 Expected income tax benefit base on statutory rate of 35% $ (1,649,000) $ (1,288,000) $ (2,086,000) Meals and entertainment 7,000 10,000 10,000 Non-deductible penalties 21,000 19,000 9,000 Warrant derivative liability (54,000) (131,000) 484,000 Valuation allowance 1,675,000 1,390,000 1,583,000 Income tax expense (benefit) $ - $ - $ - The Company has reviewed the tax positions taken and concluded that it does not have to book a liability for uncertain tax positions. Management has determined that the Company and its subsidiaries Medical and International are subject to examination of their income tax filings in the United States and state jurisdictions for the 2014 2016

401(k) and Profit Sharing Plan

401(k) and Profit Sharing Plan	12 Months Ended
	Jun. 30, 2016
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	13. 401(k) and Profit Sharing Plan The Company has a 401(k) plan, which commenced in fiscal year 2007, covering all eligible full-time employees of the Company. Contributions to the 401(k) plan are made by the participants to their individual accounts through payroll withholding. The 401(k) plan also allows the Company to make contributions at the discretion of management. To date, the Company has not made any contributions to the 401(k) plan.

Distribution Agreements

Distribution Agreements	12 Months Ended
	Jun. 30, 2016
Distribution Agreements [Abstract]
Significant Agreements Disclosure [Text Block]	14. Distribution Agreements On June 18, 2014, the Company entered into an agreement with MedikorPharma-Ural LLC as the distributor in the Russian Federation. The agreement provides the distributor with the ability to sell the entire product line in the Russian Federation. The Company has terminated its agreement with the German distributor for distribution of the GliaSite ®

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	15. Commitments and Contingencies Royalty Agreement for Invention and Patent Application A former employee and shareholder of the Company previously assigned his rights, title and interest in an invention to IsoRay Products LLC (a predecessor company) in exchange for a royalty equal to 1 The Company must also pay a royalty of 2 During fiscal years 2016, 2015 and 2014, the Company recorded royalty expenses of $ 18,317 14,448 10,106 Patent and Know-How Royalty License Agreement The Company is the holder of an exclusive license to use certain "know-how" developed by one of the founders of a predecessor to the Company and licensed to the Company by the Lawrence Family Trust, a Company shareholder. The terms of this license agreement require the payment of a royalty based on the Net Factory Sales Price, as defined in the agreement, of licensed product sales. Because the licensor's patent application was ultimately abandoned, only a 1 The licensor of the "know-how" has disputed management's contention that it is not using this "know-how". On September 25, 2007 and again on October 31, 2007, the Company participated in nonbinding mediation regarding this matter; however, no settlement was reached with the Lawrence Family Trust. After additional settlement discussions, which ended in April 2008, the parties failed to reach a settlement. The parties may demand binding arbitration at any time. Isotope Purchase Agreement In December 2015, the Company completed negotiations with The Open Joint Stock Company (located in Russia) for the purchase of Cs-131 manufactured by the Institute of Nuclear Materials. The total purchase agreement, worth approximately $ 1 590,000 Operating Lease Agreements The Company leases office and laboratory space and production and office equipment under non-cancelable operating leases. The lease agreements require monthly lease payments and expire on various dates through April 2019 (including renewal dates). In April 2016, the Company agreed to a modification which became effective May 1, 2016. The lease modification included a contractually permitted rent increase which is based on a CPI index which was 0.7 Year ending June 30, Amount 2017 $ 282,484 2018 282,484 2019 235,403 $ 800,371 For the Year Ended June 30, 2016 2015 2014 Rental expense $ 292,350 $ 280,007 $ 276,395 Royalty Agreements for Licensed Intellectual Property related to the GliaSite® RTS In June 2011 the Company entered into a license agreement with Dr. Reddy’s Laboratory Ltd for the exclusive use of its intellectual property related to the GliaSite® Radiation Therapy System (GliaSite® RTS). In April 2016 the Company provided to Dr. Reddy’s Laboratory Ltd notice of intent to terminate the license agreement. The license agreement termination was effective June 30, 2016. A final prorated royalty payment of $ 15,000 The Company recorded royalty expenses related to the licensed intellectual property utilized in the manufacture and sale of the GliaSite ® For the Year Ended June 30, 2016 2015 2014 Royalty expense $ 27,500 $ 20,138 $ 20,366 In June 2010 the Company entered into a license agreement with Hologics, Inc. for the exclusive use of its intellectual property related to Iotrex ® ® 359 The Company recorded royalty expenses related to the licensed intellectual property utilized in the manufacture and sale of the Iotrex ® For the Year Ended June 30, 2016 2015 2014 Royalty expense $ - $ 898 $ 2,214 Class Action Lawsuit Related to Press Release On May 22, 2015, the first of three lawsuits was filed against IsoRay, Inc. and two of its officers – Dwight Babcock (the Company’s retired CEO) and Brien Ragle, CFO – related to a press release on May 20, 2015 regarding a May 19 online publication of the peer-reviewed article in the journal Brachytherapy titled “ Analysis of Stereotactic Radiation vs. Wedge Resection vs. Wedge Resection Plus Cesium-131 Brachytherapy in Early-Stage Lung Cancer On October 16, 2015, an amended complaint was filed with more detailed allegations relating to violations of federal securities laws and requesting damages through a jury trial. Mr. Ragle was dismissed from the complaint. On December 15, 2015, IsoRay filed a motion to dismiss the complaint altogether. Oral argument was scheduled on this motion on April 2016 but was rescheduled at the request of the plaintiff’s attorney to May 12, 2016. On April 1, 2016, IsoRay filed a reply in Support of Motion to Dismiss Amended Complaint for Violations of the Federal Securities Laws. IsoRay believes the lawsuit is without merit and is seeking its dismissal. On May 12, 2016, the scheduled hearing on the IsoRay, Inc. motion to dismiss the securities lawsuit against the Company was held at the United States District Court for the Eastern District of Washington in Yakima, WA before Senior Judge Lonny R. Suko. On June 1, 2016, Judge Suko entered an order denying IsoRay's motion to dismiss. The order did not adjudicate the merits of the lawsuit. No other issues were decided in the ruling. A trial date has not yet been set. On June 15, 2016, IsoRay filed its answer to the amended complaint. Lead plaintiffs’ motion for class certification is due to be filed no later than January 5, 2017. A ten-day jury trial has been scheduled for June 18, 2018, along with a timeline for pre-trial actions by both IsoRay and the lead plaintiffs. Management believes that this suit is without merit and will continue to defend it vigorously in the court of law. Therefore, we have not recorded a liability relating to the litigation as of June 30, 2016. Property Transaction between Medical and The Port of Benton On September 10, 2015, the Company’s operating subsidiary, Medical, entered into a Real Estate Purchase and Sale Agreement with The Port of Benton (Port), a municipal corporation of the State of Washington. The Agreement is for the sale of undeveloped real property of approximately 4.2 The Port Commissioners amended at their monthly meeting the Development Plan with construction to start on or before January 31, 2017. The Company remains obligated to complete construction of the facility within 12 months of breaking ground on the project. Medical is bound to comply with a Development Plan for a ten-year period, the requirements of which include but are not limited to: (1) Certain specified site configurations and design with a minimum of 12,000 4,000 (2) Completion of all construction in two years; (3) Use of facility as primary production facility for ten ( 10 (4) Provision of jobs for not less than 25 The purchase price for the property was adjusted in consideration of the Development Plan’s covenants. Failure to comply with these covenants will result in a breach of the Agreement and if not cured, will obligate Medical to pay the Port the difference in the sales price and the appraised value of the property at the time of default. The Benton County 2015 assessed value of the land was $ 423,720 256,000 Employment Agreements Thomas LaVoy Mr. LaVoy took office as Chief Executive Officer on February 15, 2016. In connection with his appointment as CEO, the Company entered into an Executive Employment Agreement (LaVoy Agreement) with Mr. LaVoy for an initial term of three years subject to successive one year renewals. Under the LaVoy Agreement, Mr. LaVoy receives an annual salary of $ 300,000 bonus plan adopted by the Board in 2015 whereby he was eligible to receive a quarterly bonus of three percent ( 3 15 Mr. LaVoy received options to purchase 250,000 The LaVoy Agreement provides severance pay for the remaining term of the LaVoy Agreement or a one year period, whichever is longer. Mr. LaVoy’s employment may be terminated upon death, disability, by the Company for Cause or by Mr. LaVoy for “Good Reason.” If Mr. LaVoy’s employment is terminated by mutual agreement, by the Company without Cause, or by Mr. LaVoy for “Good Reason,” then he will be paid his unpaid salary, bonus and expenses through the date of termination, in addition to severance pay. If employment terminates for any other reason, then Mr. LaVoy only receives any unpaid salary, bonuses and expenses through the date of termination. “Good Reason” means material adverse change in Mr. LaVoy’s title, authority, duties or responsibilities. Mr. LaVoy is subject to standard confidentiality provisions and a non-compete, non-solicitation covenant for a one year period following termination of employment. Michael Krachon Mr. Krachon was hired as Vice President of Sales and Marketing on March 7, 2016. In connection with his hire, the Company entered into an Employment Agreement (Krachon Agreement) with Mr. Krachon for an initial term of three years subject to successive one year renewals. Under the Krachon Agreement, Mr. Krachon receives an annual salary of $ 225,000 bonus plan adopted by the Board in 2015 whereby he was be eligible to receive a quarterly bonus of three percent (3%) of his annual salary for any increase in revenue for a fiscal quarter of fifteen percent (15%) or more over the prior year’s corresponding fiscal quarter and an additional annual bonus of three percent ( 3 15 Mr. Krachon received options to purchase 125,000 The Krachon Agreement provides severance pay for a one year period. Mr. Krachon’s employment may be terminated upon death, disability, by the Company for Cause or by Mr. Krachon for “Good Reason.” If Mr. Krachon’s employment is terminated by mutual agreement, by the Company without Cause, or by Mr. Krachon for “Good Reason,” then he will be paid his unpaid salary, bonus and expenses through the date of termination, in addition to severance pay. If employment terminates for any other reason, then Mr. Krachon only receives any unpaid salary, bonuses and expenses through the date of termination. “Good Reason” means material adverse change in Mr. Krachon’s title, authority, duties or responsibilities. Mr. Krachon is subject to standard confidentiality provisions and a non-compete, non-solicitation covenant for a one year period following termination of employment.

Concentrations of Credit and Ot

Concentrations of Credit and Other Risks	12 Months Ended
	Jun. 30, 2016
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	16. Concentrations of Credit and Other Risks The Company's financial instruments that were exposed to concentrations of credit risk consist primarily of cash and cash equivalents, certificates of deposit, accounts receivable and certificates of deposit, non-current. The Company's certificates of deposit and certificates of deposit, non-current are maintained in the Certificate of Deposit Account Registry Service (CDARS®) through Alliance Bank of Arizona and at Columbia State Bank at June 30, 2016. The CDARS system provides the Company access to Federal Deposit Insurance Corporation (FDIC) guarantees on multi-million dollar CD deposits through a single financial institution. The Company's cash and cash equivalents were maintained with high-quality financial institutions at June 30, 2016 and 2015, respectively. The accounts are guaranteed by the (FDIC) up to $250,000. At June 30, 2016 and 2015, respectively, all cash balances were guaranteed by the FDIC. Year ended June 30, Facility 2016 2015 2014 El Camino, Los Gatos, & other facilities 1 24.20 % 24.16 % 26.75 % Bon Secours DePaul and Maryview Medical Center 2 9.03 % 11.72 % 6.51 % 1 – This group of facilities individually do not aggregate to more than 10% of total Company product sales. They are serviced by the same physician group, one of whom is our Medical Director. 2 – These two facilities are part of the same network and currently share one physician who performs procedures in both facilities. Individually, these facilities would not meet the 10% criteria, however, in aggregate, they do. The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary. Inventories Most components used in the Company's product are purchased from outside sources. Certain components are purchased from single suppliers. The failure of any such supplier to meet its commitment on schedule could have a material adverse effect on the Company's business, operating results and financial condition. If a sole-source supplier, a supplier of Cs-131 or a supplier of irradiated barium were to go out of business or otherwise become unable to meet its supply commitments, the process of locating and qualifying alternate sources could require up to several months, during which time the Company's production could be delayed. Such delays could have a material adverse effect on the Company's business, operating results and financial condition. Sanctions placed on financial transactions with Russian banking institutions may interfere with the Company’s ability to transact business in Russia on a temporary or other basis resulting in an interruption of the Cs-131 supply which could have a temporary material adverse effect on the Company’s business, operating results and financial condition. As of March 31, 2016, the Company discontinued the GliaSite ® ® 72,200

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	17. Related Party Transactions During the fiscal years 2016, 2015 and 2014, the Company engaged the services of APEX Data Systems, Inc. (APEX), owned by Dwight Babcock, former Chairman and Chief Executive Officer, to build and maintain a web interfaced data collection application to aggregate patient data in a controlled environment. An alternative vendor began providing these services beginning January 2016. For the fiscal year 2016, the Company incurred costs attributed to APEX for website modifications and maintenance of $ 6,000 12,000 12,000 6,000 12,000 12,000 0 0 3,720 0 2,000 During fiscal year 2016, the Company engaged GO Intellectual Capital, LLC (GO) for marketing services in support of the Company’s rebranding effort. Michael McCormick, a member of the Company Board of Directors, is a 1/3 owner of GO. A statement of work was developed defining the scope of the effort and the deliverables to the Company including a new logo with brand messaging and communication tools including a website, sales presentation tools and a public relations strategy. For the fiscal year 2016, the Company paid to GO $ 105,659

Quarterly Financial Data

Quarterly Financial Data	12 Months Ended
	Jun. 30, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	18. Quarterly Financial Data (unaudited) The following table provides the selected quarterly financial data for fiscal years 2016 and 2015: Quarters ended September 30, December 31, March 31, June 30, 2015 2015 2016 2016 Net revenue $ 1,261,322 $ 1,189,008 $ 1,198,701 $ 1,120,245 Gross profit/(loss) $ 83,459 $ 26,911 $ 66,304 $ (47,520) Net loss $ (1,019,110) $ (1,311,588) $ (1,195,297) $ (1,184,813) Net loss per share – basic and diluted 1 $ (0.02) $ (0.02) $ (0.02) $ (0.02) Shares used in basic and diluted per share calculation 55,012,901 55,013,553 55,022,668 55,010,619 Quarters ended September 30, December 31, March 31, June 30, 2014 2014 2015 2015 Net revenue $ 1,042,101 $ 1,065,585 $ 1,158,109 $ 1,340,744 Gross profit/(loss) $ (54,802) $ (37,964) $ 55,197 $ 204,962 Net loss $ (785,862) $ (906,954) $ (953,553) $ (1,034,682) Net loss per share – basic and diluted 1 $ (0.01) $ (0.02) $ (0.02) $ (0.02) Shares used in basic and diluted per share calculation 54,868,053 54,883,445 54,883,551 54,900,828 1 – Due to rounding, the total of the individual quarters and the year-end calculation on the Consolidated Statement of Operations may be different.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP), and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries (collectively the Company). All significant inter-company transactions and balances have been eliminated in consolidation.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are held in various financial institutions in the United States.
Investment, Policy [Policy Text Block]	Certificates of Deposit Certificates of deposit with original maturities greater than three months and remaining maturities less than one year are classified as "Certificates of deposit" and included in current assets. Certificates of deposit with remaining maturities greater than one year are classified as ”Certificates of deposit, non-current” and are included in noncurrent assets.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable Accounts receivable are stated at the amount that management of the Company expects to collect from outstanding balances. Management provides for probable uncollectible amounts through an allowance for doubtful accounts. Additions to the allowance for doubtful accounts are based on management's judgment, considering historical experience with write-offs, collections and current credit conditions. Balances which remain outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts and a credit to the applicable accounts receivable. Payments received subsequent to the time that an account is written off are treated as bad debt recoveries.
Inventory, Policy [Policy Text Block]	Inventory Inventory is reported at the lower of cost or market. Cost of raw materials is determined using the weighted average method. Cost of work in process and finished goods is computed using standard cost, which approximates actual cost, on a first-in, first-out basis. The cost of materials and production costs contained in inventory that are not useable due to the passage of time, and resulting loss of bio-effectiveness, are written off to cost of product sales at the time it is determined that the product is no longer useable. Materials contained in inventory that are components of a discontinued product are classified as a non-recurring charge to general and administrative expense.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Fixed assets are capitalized and carried at cost less accumulated depreciation. Normal maintenance and repairs are charged to expense as incurred. When any assets are sold or otherwise disposed of, the cost and accumulated depreciation are reversed with any resulting gain or loss being recognized on the consolidated statement of operations. Production equipment 3 7 Office equipment 2 5 Furniture and fixtures 2 5 Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Management periodically reviews the net carrying value of all of its long-lived assets on an asset by asset basis. An impairment loss is recognized if the carrying amount of a defined asset group is not recoverable and exceeds its fair value. Although management has made its best estimate of the factors that affect the carrying value based on current conditions, it is reasonably possible that changes could occur which could adversely affect management's estimate of net cash flows expected to be generated from its assets that could result in an impairment adjustment.
Other Assets [Policy Text Block]	Prepaid expenses and other assets, which include deferred charges, patents and licenses, are stated at cost, less accumulated amortization. Amortization of patents is computed using the straight-line method over the estimated economic useful lives of the assets. Licenses include costs related to licenses pertaining to the use of technology or operational licenses. These licenses are recorded at stated cost, less accumulated amortization. Amortization of licenses is computed using the straight-line method over the estimated economic useful lives of the assets. The Company periodically reviews the carrying values of licenses and evaluates the recorded basis for any impairment. Any impairment is recognized when the expected future operating cash flows to be derived from the licenses are less than their carrying value. The Company periodically reviews the carrying values of patents and any related impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value.
Asset Retirement Obligations, Policy [Policy Text Block]	Asset Retirement Obligation The estimated fair value of the future retirement costs of the Company's leased assets and the costs for the decontamination and reclamation of equipment located within the footprint leased asset are recorded as a liability on a discounted basis when a contractual obligation exists; an equivalent amount is capitalized to property and equipment. The initial recorded obligation is discounted using the Company's credit-adjusted risk-free rate and is reviewed periodically for changes in the estimated future costs underlying the obligation. The Company amortizes the initial amount capitalized to property and equipment and recognizes accretion expense in connection with the discounted liability over the estimated remaining useful life of the leased assets.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments The Company discloses the fair value of financial instruments, both assets and liabilities, recognized and not recognized in the balance sheet, for which it is practicable to estimate the fair value. The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than a forced liquidation sale. At June 30, 2016 and 2015, the carrying value of financial instruments which include certificates of deposit and restricted cash, approximated fair value.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurement ASC Topic 820, Fair Value Measurements At June 30, 2016 and 2015, there were no assets or liabilities measured at fair-value on a recurring basis which were measured using Level 3 inputs. The Company had a single liability, the derivative warrant liability, which was measured at fair value on a recurring basis using Level 2 inputs during the years ended June 30, 2016, 2015 and 2014. Certain assets and liabilities are measured at fair value on a non-recurring basis; that is, the instruments are not measured at fair value on an ongoing basis, but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). With the exception of the asset retirement obligation (Note 9), the Company had no assets or liabilities measured at fair value on a nonrecurring basis during the three years ended June 30, 2016. The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. Fair value at June 30, 2016 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 10,139,026 $ 10,139,026 $ - $ - Warrant derivative liability 27,000 - 27,000 - Fair value at June 30, 2015 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,226,740 $ 5,226,740 $ - $ - Warrant derivative liability 181,000 - 181,000 - The Company’s cash and cash equivalent instruments are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company’s warrant derivative liability is valued using the Black-Scholes option pricing model which requires a variety of inputs as described in Note 11. Such instruments are typically included in Level 2.
Derivatives, Policy [Policy Text Block]	Warrant Derivative Liabilities For the warrant derivative liabilities which are measured at fair value on a recurring basis, the Company uses the Black-Scholes valuation model as described in Note 11.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue related to product sales when (i) persuasive evidence of an arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. The Company recognizes revenue once the product has been shipped to the customer. Prepayments, if any, received from customers prior to the time that products are shipped are recorded as deferred revenue. In these cases, when the related products are shipped, the amount recorded as deferred revenue is then recognized as revenue. The Company accrues for sales returns and other allowances at the time of shipment.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Costs Shipping and handling costs include charges associated with delivery of goods from the Company's facilities to its customers and are reflected in cost of product sales. Shipping and handling costs paid to the Company by its customers are classified as product sales.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Compensation The Company measures and recognizes expense for all share-based payments at fair value. The Company uses the Black-Scholes option valuation model to estimate fair value for all stock options on the date of grant. For stock options that vest over time, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year recognized.
Advertising Costs, Policy [Policy Text Block]	Advertising and Marketing Costs For the Years Ended June 30, 2016 2015 2014 Advertising and marketing costs expensed (including tradeshows) $ 157,347 $ 151,197 $ 114,313 At June 30, 2016 2015 Prepaid marketing expenses deferred until event occurs $ 12,222 $ 9,600
Commitments and Contingencies, Policy [Policy Text Block]	Legal Contingencies The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. Estimating probable losses requires analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. Currently, the Company does not believe any probable legal proceedings or claims will have a material adverse effect on its financial position or results of operations. However, if actual or estimated probable future losses exceed the Company's recorded liability for such claims, it would record additional charges as other expense during the period in which the actual loss or change in estimate occurred.
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are accounted for under the liability method. Under this method, the Company provides deferred income taxes for temporary differences that will result in taxable or deductible amounts in future years based on the reporting of certain costs in different periods for financial statement and income tax purposes. This method also requires the recognition of future tax benefits such as net operating loss carry-forwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment of the change. In the event that the Company is assessed penalties and or interest, penalties will be charged to other operating expense and interest will be charged to interest expense in the period that they are assessed.
Earnings Per Share, Policy [Policy Text Block]	Income (Loss) Per Common Share Basic earnings per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not include the impact of any potentially dilutive common stock equivalents, including preferred stock, common stock warrants or options that are potentially convertible into common stock, as those would be antidilutive due to the Company's net loss position. June 30, 2016 2015 2014 Preferred stock 59,065 59,065 59,065 Common stock warrants 230,087 385,800 444,747 Common stock options 2,925,059 2,418,282 2,314,422 Total potential dilutive securities 3,214,211 2,863,147 2,818,234
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company's fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company's production facilities; inputs used in the calculation of expense related to share-based compensation including volatility, estimated lives and forfeiture rates of options granted; and the inputs to the Black-Scholes calculation to estimate the fair value of the derivative warrant liability and the related gain or loss. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, "Revenue from Contracts with Customers" (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, "Revenue Recognition". The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11: Inventory. The guidance requires an entity’s management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements. In November 2015, the FASB issued an ASU 2015-17 to simplify the balance sheet classification of deferred taxes. This update requires all deferred tax assets and liabilities to be reported as non-current in the consolidated balance sheets. This update will be effective as of the beginning of fiscal 2018. This update is not expected to have a material impact on the Company’s consolidated financial statements . In February 2016, the FASB issued ASU 2016-02 Leases (Subtopic 842), which will require lessees to recognize assets and liabilities on the balance sheet for the rights and obligations created by most leases. The update is effective for annual and interim reporting periods beginning after December 15, 2018. We are currently evaluating the impact of the guidance on the Company’s consolidated financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Schedule Of Estimated Useful Lives Of Assets [Table Text Block]	Production equipment 3 7 Office equipment 2 5 Furniture and fixtures 2 5
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Fair value at June 30, 2016 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 10,139,026 $ 10,139,026 $ - $ - Warrant derivative liability 27,000 - 27,000 - Fair value at June 30, 2015 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,226,740 $ 5,226,740 $ - $ - Warrant derivative liability 181,000 - 181,000 -
Schedule of Other Operating Cost and Expense, by Component [Table Text Block]	Advertising costs are expensed as incurred except for the cost of tradeshows and related marketing materials which are deferred until the tradeshow occurs. For the Years Ended June 30, 2016 2015 2014 Advertising and marketing costs expensed (including tradeshows) $ 157,347 $ 151,197 $ 114,313 At June 30, 2016 2015 Prepaid marketing expenses deferred until event occurs $ 12,222 $ 9,600
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Securities that could be dilutive in the future are as follows: June 30, 2016 2015 2014 Preferred stock 59,065 59,065 59,065 Common stock warrants 230,087 385,800 444,747 Common stock options 2,925,059 2,418,282 2,314,422 Total potential dilutive securities 3,214,211 2,863,147 2,818,234

Certificates of deposit (Tables

Certificates of deposit (Tables)	12 Months Ended
	Jun. 30, 2016
Investments, All Other Investments [Abstract]
Schedule of Cost Method Investments [Table Text Block]	Under 90 91 days to Six months to Greater days six months 1 year than 1 year CDARS, as of June 30, 2016 $ $ $ 2,247,111 $ 2,973,348 CDARS, as of June 30, 2015 $ 3,523,167 $ 500,064 $ 5,339,343 $ 5,106,775

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consisted of the following: June 30, 2016 2015 Raw materials $ 155,178 $ 143,669 Work in process 160,936 204,760 Finished goods 18,281 55,526 Total inventory $ 334,395 $ 403,955
Schedule of Inventory, Noncurrent [Table Text Block]	June 30, 2016 2015 Enriched barium, non-current $ 469,758 $ 469,758 Raw materials, non-current 120,858 100,096 Total inventory, non-current $ 590,616 $ 569,854

Prepaid Expenses and Other Cu29

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Jun. 30, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	Prepaid expenses and other current assets consisted of the following: June 30, 2016 2015 Prepaid insurance $ 46,108 $ 30,578 Other prepaid expenses 230,933 206,326 Other current assets 26,693 26,693 $ 303,734 $ 263,597

Property & Equipment (Tables)

Property & Equipment (Tables)	12 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	June 30, 2016 2015 Land $ 168,459 $ - Equipment 3,605,815 3,553,774 Leasehold improvements 4,129,977 4,129,977 Other 1 213,567 5,925 Property and equipment 8,117,818 7,689,676 Less accumulated depreciation (7,541,126) (7,114,836) Property and equipment, net $ 576,692 $ 574,840 1 – Plant and equipment, not placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet. Also included at June 30, 2016 are costs associated with advance planning and design work on the Company’s new production facility. Year Ended June 30, 2016 2015 2014 Depreciation expense $ 470,851 $ 576,380 $ 685,396

Other Assets, net (Tables)

Other Assets, net (Tables)	12 Months Ended
	Jun. 30, 2016
Other Assets [Abstract]
Schedule of Other Assets [Table Text Block]	June 30, 2016 2015 Deferred charges $ $ 46,541 Patents and trademarks, net of accumulated amortization of $215,497 and $134,559, respectively. 150,533 198,490 $ 150,533 $ 245,031 Year Ended June 30, 2016 2015 2014 Amortization expense on patents and trademarks $ 17,176 $ 25,226 $ 18,468 Change in estimate on patents and trademarks 1 63,762 - - Total amortization expense $ 80,938 $ 25,226 $ 18,468 1 The change in estimate is the result of the review of information contained in the amortization assumptions which is based on new information resulted in a non-recurring change in the amortization expense.
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Future amortization is expected to be as follows: FY2017 $ 17,612 FY2018 17,152 FY2019 16,905 FY2020 16,368 FY2021 16,368 Thereafter 66,128 $ 150,533

Asset Retirement Obligation (Ta

Asset Retirement Obligation (Tables)	12 Months Ended
	Jun. 30, 2016
Asset Retirement Obligation Disclosure [Abstract]
Schedule of Change in Asset Retirement Obligation [Table Text Block]	The ARO changed as follows: Year Ended June 30, 2016 2015 Beginning balance $ 947,849 $ 866,560 Accretion of discount 88,915 81,289 Gain on change in ARO estimate (456,284) 81,289 Ending balance $ 580,480 $ 947,849

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The weighted average fair value of stock option awards granted and the key assumptions used in the Black-Scholes valuation model to calculate the fair value are as follows: For the Year Ended June 30, 2016 2015 2014 Weighted average fair value $0.60 $1.11 $1.28 Options issued 1,185,500 395,000 430,000 Exercise price $0.64 to $1.53 $1.47 $0.58 to $2.46 Expected term (in years) 1 to 5 4 to 5 4 to 5 Risk-free rate 0.51% to 1.62% 1.42% to 1.65% 1.48% to 1.85% Volatility 106% - 118% 107% 106% to 132%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table presents the share-based compensation expense: For the Year Ended June 30, 2016 2015 2014 Cost of product sales $ 70,842 $ 44,798 $ 17,818 Research and development expense 14,266 17,107 13,486 Sales and marketing expense 23,459 11,608 3,588 General and administrative expense 181,745 131,751 151,095 Total share-based compensation $ 290,312 $ 205,264 $ 185,987
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	A summary of stock option information within the Company's share-based compensation plans during the fiscal years is presented below: Options Outstanding Price (a) Life (b) Value (c) Balance at June 30, 2013 2,305,072 $ 1.83 4.93 $ 115,302 Granted (d) 380,000 1.81 Expired/Forfeited (19,667) 0.61 Exercised (350,983) 0.76 Balance at June 30, 2014 2,314,422 $ 2.00 4.69 $ 3,186,916 Granted (d) 395,000 1.41 Expired/Forfeited (84,236) 4.15 Exercised (206,904) 1.03 Balance at June 30, 2015 2,418,282 $ 1.91 4.71 $ 691,789 Granted (d) 1,185,500 .87 Expired (459,594) 3.48 Forfeited (162,869) 1.67 Exercised (56,260) .89 Balance at June 30, 2016 2,925,059 $ 1.21 6.93 $ 262,557 Vested and expected to vest at June 30, 2016 2,686,525 $ 1.20 6.88 $ 256,233 Exercisable at June 30, 2016 2,561,194 $ 1.18 6.73 $ 250,373 (a) Weighted average exercise price per share. (b) Weighted average remaining contractual life. (c) Aggregate intrinsic value. (d) All options granted had exercise prices equal to or greater than the ending closing market price of the Company's common stock on the grant date. The options were granted to employees and management by the Board of Directors and had vesting periods from immediate to five years. For the Year Ended June 30, 2016 2015 2014 Aggregate intrinsic value of options exercised $ 24,595 $ 306,620 $ 548,928

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2016
Stockholders' Equity Note [Abstract]
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]	For the Year Ended June 30, 2016 2015 2014 Change in fair value of the warrant derivative liability $ 154,000 $ 374,605 $ (1,382,134) A summary of the change in fair value of derivative warrant liability is as follows for the fiscal years presented. Quantity 1 Amount Balance at June 30, 2013 713,601 $ 104,000 Change in fair value 1,382,000 Warrants corrected 10,869 - Warrants redeemed in cashless exercise (22,472) - Warrants exercised (463,702) (913,000) Balance at June 30, 2014 238,296 $ 573,000 Change in fair value (374,605) Warrants exercised (13,209) (17,395) Balance at June 30, 2015 225,087 $ 181,000 Change in fair value (154,000) Balance at June 30, 2016 225,087 $ 27,000
Schedule of Stockholders Equity Note Warrants or Rights [Table Text Block]	The following table summarizes the activity of all stock warrants and weighted average exercise prices including the derivative warrants discussed above. Warrants Price (a) Balance at June 30, 2013 1,957,033 $ 1.38 Corrections 26,939 1.31 Warrants redeemed in cashless exercise (22,520) 0.96 Warrants exercised (7,165,443) 0.86 Warrants granted 5,648,738 0.72 Balance at June 30, 2014 444,747 1.43 Warrants exercised (58,947) 1.38 Balance at June 30, 2015 385,800 1.22 Warrants expired (155,713) 1.63 Balance at June 30, 2016 230,087 $ .94 (a) Weighted average exercise price per share.
Schedule Of Stockholders Equity Note Warrants Or Rights By Exercise Price Range [Table Text Block]	Number of Range of Expiration Warrants Exercise Prices 1 Date 199,437 0.94 October 2016 25,650 0.94 December 2016 5,000 0.98 June 2017 230,087 1 – Exercise prices have been rounded to the nearest whole cent.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of June 30, 2016 2015 Fixed assets $ 610,000 $ 546,000 Share-based compensation 545,000 443,000 Reserves 13,000 11,000 Other accruals 119,000 85,000 Asset retirement obligation 203,000 332,000 Net operating loss carryforwards 19,110,000 17,508,000 Total deferred tax assets 20,600,000 18,925,000 Valuation allowance (20,600,000) (18,925,000) Total $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the year ended June 30, 2016 2015 2014 Expected income tax benefit base on statutory rate of 35% $ (1,649,000) $ (1,288,000) $ (2,086,000) Meals and entertainment 7,000 10,000 10,000 Non-deductible penalties 21,000 19,000 9,000 Warrant derivative liability (54,000) (131,000) 484,000 Valuation allowance 1,675,000 1,390,000 1,583,000 Income tax expense (benefit) $ - $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year ending June 30, Amount 2017 $ 282,484 2018 282,484 2019 235,403 $ 800,371 For the Year Ended June 30, 2016 2015 2014 Rental expense $ 292,350 $ 280,007 $ 276,395
Unrecorded Unconditional Purchase Obligations Disclosure [Table Text Block]	For the Year Ended June 30, 2016 2015 2014 Royalty expense $ 27,500 $ 20,138 $ 20,366 For the Year Ended June 30, 2016 2015 2014 Royalty expense $ - $ 898 $ 2,214

Concentrations of Credit and 37

Concentrations of Credit and Other Risks (Tables)	12 Months Ended
	Jun. 30, 2016
Risks and Uncertainties [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	Year ended June 30, Facility 2016 2015 2014 El Camino, Los Gatos, & other facilities 1 24.20 % 24.16 % 26.75 % Bon Secours DePaul and Maryview Medical Center 2 9.03 % 11.72 % 6.51 % 1 – This group of facilities individually do not aggregate to more than 10% of total Company product sales. They are serviced by the same physician group, one of whom is our Medical Director. 2 – These two facilities are part of the same network and currently share one physician who performs procedures in both facilities. Individually, these facilities would not meet the 10% criteria, however, in aggregate, they do.

Quarterly Financial Data (Table

Quarterly Financial Data (Tables)	12 Months Ended
	Jun. 30, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Table Text Block]	Quarters ended September 30, December 31, March 31, June 30, 2015 2015 2016 2016 Net revenue $ 1,261,322 $ 1,189,008 $ 1,198,701 $ 1,120,245 Gross profit/(loss) $ 83,459 $ 26,911 $ 66,304 $ (47,520) Net loss $ (1,019,110) $ (1,311,588) $ (1,195,297) $ (1,184,813) Net loss per share – basic and diluted 1 $ (0.02) $ (0.02) $ (0.02) $ (0.02) Shares used in basic and diluted per share calculation 55,012,901 55,013,553 55,022,668 55,010,619 Quarters ended September 30, December 31, March 31, June 30, 2014 2014 2015 2015 Net revenue $ 1,042,101 $ 1,065,585 $ 1,158,109 $ 1,340,744 Gross profit/(loss) $ (54,802) $ (37,964) $ 55,197 $ 204,962 Net loss $ (785,862) $ (906,954) $ (953,553) $ (1,034,682) Net loss per share – basic and diluted 1 $ (0.01) $ (0.02) $ (0.02) $ (0.02) Shares used in basic and diluted per share calculation 54,868,053 54,883,445 54,883,551 54,900,828 1 – Due to rounding, the total of the individual quarters and the year-end calculation on the Consolidated Statement of Operations may be different.

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Jun. 30, 2016
Production Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Production Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Summary of Significant Accoun40

Summary of Significant Accounting Policies (Details 1) - Fair Value, Measurements, Recurring [Member] - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 10,139,026	$ 5,226,740
Warrant derivative liability	27,000	181,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	10,139,026	5,226,740
Warrant derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Warrant derivative liability	27,000	181,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Warrant derivative liability	$ 0	$ 0

Summary of Significant Accoun41

Summary of Significant Accounting Policies (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Marketing and Advertising Expense [Line Items]
Advertising and marketing costs expensed (including tradeshows)	$ 157,347	$ 151,197	$ 114,313
Prepaid marketing expenses deferred until event occurs	$ 12,222	$ 9,600

Summary of Significant Accoun42

Summary of Significant Accounting Policies (Details 3) - shares	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,214,211	2,863,147	2,818,234
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,925,059	2,418,282	2,314,422
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	59,065	59,065	59,065
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	230,087	385,800	444,747

Certificates of deposit (Detail

Certificates of deposit (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Under 90 Days [Member]
Schedule of Cost-method Investments [Line Items]
Investment Owned, at Cost		$ 3,523,167
91 Days to Six Months [Member]
Schedule of Cost-method Investments [Line Items]
Investment Owned, at Cost		500,064
Six Months to 1 Year [Member]
Schedule of Cost-method Investments [Line Items]
Investment Owned, at Cost	2,247,111	5,339,343
Greater than 1 Year [Member]
Schedule of Cost-method Investments [Line Items]
Investment Owned, at Cost	$ 2,973,348	$ 5,106,775

Certificates of deposit (Deta44

Certificates of deposit (Details Textual)	12 Months Ended
	Jun. 30, 2016USD ($)
Certificates of deposit [Line Items]
Federal Deposit Insurance Corporation Limits On Deposits In Financial Institutions	$ 250,000

Inventory (Details)

Inventory (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Inventory [Line Items]
Raw materials	$ 155,178	$ 143,669
Work in process	160,936	204,760
Finished goods	18,281	55,526
Total inventory	334,395	403,955
Total inventory, non-current	590,616	569,854
Enriched Barium Inventory [Member]
Inventory [Line Items]
Total inventory, non-current	469,758	469,758
Raw Materials [Member]
Inventory [Line Items]
Total inventory, non-current	$ 120,858	$ 100,096

Inventory (Details Textual)

Inventory (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Inventory Write-down			$ 72,200	$ 0	$ 0
GliaSite® RTS [Member]
Inventory Write-down	$ 72,200	$ 72,200

Prepaid Expenses and Other Cu47

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Prepaid Expenses and Other Current Assets [Line Items]
Prepaid insurance	$ 46,108	$ 30,578
Other prepaid expenses	230,933	206,326
Other current assets	26,693	26,693
Prepaid Expense and Other Assets, Current	$ 303,734	$ 263,597

Property & Equipment (Details)

Property & Equipment (Details) - USD ($)		Jun. 30, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Property and equipment		$ 8,117,818	$ 7,689,676
Less accumulated depreciation		(7,541,126)	(7,114,836)
Property and equipment , net		576,692	574,840
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment		4,129,977	4,129,977
Other [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	[1]	213,567	5,925
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment		168,459	0
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment		$ 3,605,815	$ 3,553,774
[1]	Plant and equipment, not placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet. Also included at June 30, 2016 are costs associated with advance planning and design work on the Company’s new production facility.

Property & Equipment (Details 1

Property & Equipment (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 470,851	$ 576,380	$ 685,396

Property & Equipment (Details T

Property & Equipment (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Line Items]
Gain (Loss) on Disposition of Property Plant Equipment, Total	$ (6,512)	$ 0	$ 0
Property, Plant and Equipment, Disposals	51,071	$ 10,359	$ 59,723
GliaSite® RTS [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Disposals	43,411
Other equipment no longer in service [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Disposals	$ 7,660

Restricted Cash (Details Textua

Restricted Cash (Details Textual) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Restricted Cash and Cash Equivalents, Noncurrent	$ 181,420	$ 181,262
Certificates of Deposit [Member]
Restricted Cash and Cash Equivalents, Noncurrent	$ 181,420

Other Assets, net (Details)

Other Assets, net (Details) - USD ($)		12 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Deferred charges			$ 46,541
Patents and trademarks, net of accumulated amortization of $215,497 and $134,559, respectively.		$ 150,533	198,490
Other Assets, Noncurrent		150,533	245,031
Amortization expense on patents and trademarks		17,176	25,226	$ 18,468
Change in estimate on patents and trademarks	[1]	63,762	0	0
Total amortization expense		80,938	25,226	$ 18,468
Finite-Lived Intangible Assets, Accumulated Amortization		$ 215,497	$ 134,559
[1]	The change in estimate is the result of the review of information contained in the amortization assumptions which is based on new information resulted in a non-recurring change in the amortization expense.

Other Assets, net (Details 1)

Other Assets, net (Details 1) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
FY2017	$ 17,612
FY2018	17,152
FY2019	16,905
FY2020	16,368
FY2021	16,368
Thereafter	66,128
Finite-Lived Intangible Assets, Net	$ 150,533	$ 198,490

Asset Retirement Obligation (De

Asset Retirement Obligation (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Asset Retirement Obligation [Line Items]
Beginning balance	$ 947,849	$ 866,560
Accretion of discount	88,915	81,289	$ 74,318
Gain on change in ARO estimate	(456,284)	81,289
Ending balance	$ 580,480	$ 947,849	$ 866,560

Asset Retirement Obligation (55

Asset Retirement Obligation (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Asset Retirement Obligation [Line Items]
Asset Retirement Obligation, Period Increase Decrease In Estimate, Gain Loss	$ (456,284)	$ 81,289
Asset Retirement Obligation Assumed Inflation Factor	1.10%
Asset Retirement Obligation Assumed Credit-adjusted Risk Free Rate	5.10%
Asset Retirement Obligations, Noncurrent, Total	$ 580,480	$ 947,849
Estimated Asset Retirement Cost	$ 650,000

Share-Based Compensation (Detai

Share-Based Compensation (Details) - $ / shares	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options issued	1,185,500	395,000	430,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price		$ 1.47
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.51%	1.42%	1.48%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	1.62%	1.65%	1.85%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	106.00%		106.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	118.00%		132.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		107.00%
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Weighted average fair value	$ 0.60	$ 1.11	$ 1.28
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 1.53		$ 2.46
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years	5 years	5 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 0.64		$ 0.58
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	1 year	4 years	4 years

Share-Based Compensation (Det57

Share-Based Compensation (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	$ 290,312	$ 205,264	$ 185,987
Cost of product sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	70,842	44,798	17,818
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	14,266	17,107	13,486
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	23,459	11,608	3,588
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	$ 181,745	$ 131,751	$ 151,095

Share-Based Compensation (Det58

Share-Based Compensation (Details 2) - USD ($)		12 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Number of Options
Beginning balance outstanding		2,418,282	2,314,422	2,305,072
Granted	[1]	1,185,500	395,000	380,000
Expired/Forfeited			(84,236)	(19,667)
Expired		(459,594)
Forfeited		(162,869)
Exercised		(56,260)	(206,904)	(350,983)
Ending balance outstanding		2,925,059	2,418,282	2,314,422	2,305,072
Vested and expected to vest		2,686,525
Exercisable		2,561,194
Weighted Exercise Price
Begining balance outstanding	[2]	$ 1.91	$ 2	$ 1.83
Granted	[1],[2]	0.87	1.41	1.81
Expired/Forfeited	[2]		4.15	0.61
Expired	[2]	3.48
Forfeited	[2]	1.67
Exercised	[2]	0.89	1.03	0.76
Ending balance outstanding	[2]	1.21	$ 1.91	$ 2	$ 1.83
Vested and expected to vest	[2]	1.20
Exercisable	[2]	$ 1.18
Weighted Average Contractual Term
Outstanding	[3]	6 years 11 months 5 days	4 years 8 months 16 days	4 years 8 months 8 days	4 years 11 months 5 days
Vested and expected to vest	[3]	6 years 10 months 17 days
Exercisable	[3]	6 years 8 months 23 days
Intrinsic Value
Outstanding	[4]	$ 262,557	$ 691,789	$ 3,186,916	$ 115,302
Vested and expected to vest	[4]	256,233
Exercisable	[4]	250,373
Aggregate intrinsic value of options exercised		$ 24,595	$ 306,620	$ 548,928
[1]	All options granted had exercise prices equal to or greater than the ending closing market price of the Company's common stock on the grant date. The options were granted to employees and management by the Board of Directors and had vesting periods from immediate to five years.
[2]	Weighted average exercise price per share.
[3]	Weighted average remaining contractual life.
[4]	Aggregate intrinsic value.

Share-Based Compensation (Det59

Share-Based Compensation (Details Textual)	12 Months Ended
	Jun. 30, 2016USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total | $	$ 787,245
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 10 months 24 days
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,000,000
Officers Employees and Consultants [Member] | Employee Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,000,000
Directors Officers and Consultants [Member] | 2016 Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	4,000,000

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Class of Warrant or Right [Line Items]
Change in fair value of warrant derivative liability	$ 154,000	$ 374,605	$ (1,382,134)

Shareholders' Equity (Details 1

Shareholders' Equity (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Quantity
Balance	385,800	444,747	1,957,033
Warrants corrected			26,939
Warrants redeemed in cashless exercise			(22,520)
Warrants exercised		(58,947)	(7,165,443)
Balance	230,087	385,800	444,747
Value of warrants issued:
Change in fair value	$ (154,000)	$ (374,605)	$ 1,382,134
Derivative Warrants [Member]
Quantity
Balance	225,087	238,296	713,601
Warrants corrected			10,869
Warrants redeemed in cashless exercise			(22,472)
Warrants exercised		(13,209)	(463,702)
Balance	225,087	225,087	238,296
Value of warrants issued:
Balance	$ 181,000	$ 573,000	$ 104,000
Change in fair value	(154,000)	(374,605)	1,382,000
Warrants corrected			0
Warrants redeemed in cashless exercise			0
Warrants exercised		(17,395)	(913,000)
Balance	$ 27,000	$ 181,000	$ 573,000

Shareholders' Equity (Details 2

Shareholders' Equity (Details 2) - $ / shares		12 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Warrants
Balance		385,800	444,747	1,957,033
Corrections				26,939
Warrants redeemed in cashless exercise				(22,520)
Warrants exercised			(58,947)	(7,165,443)
Warrants granted				5,648,738
Warrants expired		(155,713)
Balance		230,087	385,800	444,747
Weighted average exercise price
Balance	[1]	$ 1.22	$ 1.43	$ 1.38
Corrections	[1]			1.31
Warrants expired	[1]	1.63
Balance	[1]	$ 0.94	1.22	1.43
Warrants redeemed in cashless exercise	[1]			0.96
Warrants exercised	[1]		$ 1.38	0.86
Warrants granted	[1]			$ 0.72
[1]	Weighted average exercise price per share.

Shareholders' Equity (Details 3

Shareholders' Equity (Details 3) - $ / shares		12 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Class of Warrant or Right [Line Items]
Number of Warrants		230,087	385,800	444,747	1,957,033
Range of Exercise Prices	[1]	$ 0.94	$ 1.22	$ 1.43	$ 1.38
Expiration Date		Expiration
Range of Exercise Price One [Member]
Class of Warrant or Right [Line Items]
Number of Warrants		199,437
Range of Exercise Prices	[2]	$ 0.94
Expiration Date		October 2,016
Range of Exercise Price Two [Member]
Class of Warrant or Right [Line Items]
Number of Warrants		25,650
Range of Exercise Prices	[2]	$ 0.94
Expiration Date		December 2,016
Range of Exercise Price Three [Member]
Class of Warrant or Right [Line Items]
Number of Warrants		5,000
Range of Exercise Prices	[2]	$ 0.98
Expiration Date		June 2,017
[1]	Weighted average exercise price per share.
[2]	Exercise prices have been rounded to the nearest whole cent.

Shareholders' Equity (Details T

Shareholders' Equity (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
	Mar. 21, 2014	Jan. 31, 2014	Aug. 29, 2013	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Preferred Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
Common Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
Preferred Stock, Shares Authorized				7,001,671		7,001,671
Payments of Ordinary Dividends, Preferred Stock and Preference Stock				$ 10,632	$ 10,632	$ 10,632	$ 10,632
Gross Proceeds From Issuance Of Stock	14,675,180		3,700,000
Preferred Stock Redemption Premium			$ 726,378	$ 0		$ 0	$ 726,378
Proceeds from Issuance or Sale of Equity	$ 13,814,742		$ 3,279,292
Common Stock, Shares, Outstanding		41,540,982		55,010,619		54,967,559		38,419,502
Common Stock [Member]
Shares Issued, Price Per Share	$ 2.60		$ 0.535
Stock Issued During Period, Shares, New Issues	5,644,300		3,800,985				3,800,985
Conversion of Stock, Shares Issued		3,121,480					3,121,480
Common Unit Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			0.816
Shares Issued, Price Per Share			$ 0.72
Class Of Warrant Or Right Term			24 months
Preferred Unit Warrants [Member]
Shares Issued, Price Per Share			$ 0.72
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,525.23
Class Of Warrant Or Right Term			24 months
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
Preferred Stock, Shares Authorized				1,000,000		1,000,000
Preferred Stock, Shares Outstanding				0		0
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
Preferred Stock, Shares Authorized				5,000,000		5,000,000
Convertible Preferred Stock Terms Of Forced Conversion				$ 4,000,000
Preferred Stock, Dividend Rate, Percentage				15.00%
Preferred Stock, Shares Outstanding				59,065		59,065
Preferred Stock, Amount of Preferred Dividends in Arrears				$ 5,316
Series C Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
Preferred Stock, Shares Authorized				1,000,000		1,000,000
Preferred Stock, Shares Outstanding				0		0
Series D Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
Preferred Stock, Shares Authorized				1,671		1,671
Preferred Stock, Shares Outstanding				0		0
Convertible Preferred Stock Maximum Ownership Interest				9.99%
Shares Issued, Price Per Share			$ 1,000
Stock Issued During Period, Shares, New Issues			1,670
Conversion of Stock, Shares Converted		1,670
Convertible Preferred Stock, Shares Issued upon Conversion			1,869.15

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Income Taxes Disclosure [Line Items]
Fixed assets	$ 610,000	$ 546,000
Share-based compensation	545,000	443,000
Reserves	13,000	11,000
Other accruals	119,000	85,000
Asset retirement obligation	203,000	332,000
Net operating loss carryforwards	19,110,000	17,508,000
Total deferred tax assets	20,600,000	18,925,000
Valuation allowance	(20,600,000)	(18,925,000)
Total	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Income Taxes Disclosure [Line Items]
Expected income tax benefit base on statutory rate of 35%	$ (1,649,000)	$ (1,288,000)	$ (2,086,000)
Meals and entertainment	7,000	10,000	10,000
Non-deductible penalties	21,000	19,000	9,000
Warrant derivative liability	(54,000)	(131,000)	484,000
Valuation allowance	1,675,000	1,390,000	1,583,000
Income tax expense (benefit)	$ 0	$ 0	$ 0

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating Loss Carryforwards [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	35.00%
Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2,014
Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open Tax Year	2,016
Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards [Line Items]
Deferred Tax Assets Valuation Allowance Percentage	100.00%	100.00%
Operating Loss Carryforwards	$ 55
Internal Revenue Service (IRS) [Member] | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2027
Internal Revenue Service (IRS) [Member] | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2035

Commitments and Contingencies68

Commitments and Contingencies (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Other Commitments [Line Items]
2,017	$ 282,484
2,018	282,484
2,019	235,403
Operating Leases, Future Minimum Payments Due	800,371
Rental expense	$ 292,350	$ 280,007	$ 276,395

Commitments and Contingencies69

Commitments and Contingencies (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Gliasite Radiation Therapy System [Member]
Other Commitments [Line Items]
Royalty expense	$ 27,500	$ 20,138	$ 20,366
Gliasite Radiation Therapy System Iotrex [Member]
Other Commitments [Line Items]
Royalty expense	$ 0	$ 898	$ 2,214

Commitments and Contingencies70

Commitments and Contingencies (Details Textual)		1 Months Ended				12 Months Ended
		Mar. 07, 2016shares	Feb. 15, 2016shares	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2016USD ($)aft²shares	Jun. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)shares
Unrecorded Unconditional Purchase Obligation [Line Items]
Area of Land | a						4.2
Number Of Employees Commitment						25
Percentage Of Royalty Rate Payable						1.00%
Purchase Obligation Expiration Date						Mar. 31, 2017
Purchase Obligation Agreement Period						1 year
Purchase Obligation						$ 1,000,000
Purchase Obligation, Due in Next Twelve Months						$ 590,000
Granted (d) | shares	[1]					1,185,500	395,000	380,000
Commitment Cpi						0.70%
Chief Executive Officer [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Officers' Compensation						$ 300,000
Deferred Compensation Arrangement with Individual, Description						bonus plan adopted by the Board in 2015 whereby he was eligible to receive a quarterly bonus of three percent (3%) of his annual salary for any increase in revenue for a fiscal quarter of fifteen percent (15%) or more over the prior years corresponding fiscal quarter and an additional annual bonus of three percent (3%) of his annual salary for any fifteen percent (15%) or more annual increase in revenue by the Company over the prior fiscal year and as subsequently modified in future years by the Compensation Committee.
Granted (d) | shares			250,000
Chief Executive Officer [Member] | Deferred Bonus [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Deferred Compensation Arrangement With Individual Increase In Revenue Percentage Minimum						15.00%
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage						3.00%
Vice President [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Officers' Compensation						$ 225,000
Deferred Compensation Arrangement with Individual, Description						bonus plan adopted by the Board in 2015 whereby he was be eligible to receive a quarterly bonus of three percent (3%) of his annual salary for any increase in revenue for a fiscal quarter of fifteen percent (15%) or more over the prior years corresponding fiscal quarter and an additional annual bonus of three percent (3%) of his annual salary for any fifteen percent (15%) or more annual increase in revenue by the Company over the prior fiscal year and as subsequently modified in future years by the Compensation Committee.
Granted (d) | shares		125,000
Vice President [Member] | Deferred Bonus [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Deferred Compensation Arrangement With Individual Increase In Revenue Percentage Minimum						15.00%
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage						3.00%
Royalty Agreement For Invention And Patent Application [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Royalty Expense						$ 18,317	$ 14,448	$ 10,106
Patent Rights Knowhow And License Agreements [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Percentage Of Royalty Rate Payable						1.00%
Royalty Agreement For Invention And Patent Application Sub Assignments [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Percentage Of Royalty Rate Payable						2.00%
Dr. Reddy’s Laboratory Ltd [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
License Agreement Expiration Date				Jun. 30, 2016
Accrued Royalties, Current						$ 15,000
Hologics Inc [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
License Agreement Expiration Date					Jul. 11, 2016
Accrued Royalties, Current						359
The Benton Country 2015 [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Land						423,720
Development Plan Amount At Risk If Failure To Comply With Covenants						$ 256,000
Capital Addition Purchase Commitments [Member] | Warehouse Space [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Minimum Building Size Specifications | ft²						12,000
Capital Addition Purchase Commitments [Member] | Office Space [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Minimum Building Size Specifications | ft²						4,000
Primary Use Agreement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Unrecorded Unconditional Purchase Obligation, Term						10 years
[1]	All options granted had exercise prices equal to or greater than the ending closing market price of the Company's common stock on the grant date. The options were granted to employees and management by the Board of Directors and had vesting periods from immediate to five years.

Concentrations of Credit and 71

Concentrations of Credit and Other Risks (Details) - Sales [Member] - Customer Concentration Risk [Member]		12 Months Ended
		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
El Camino, Los Gatos, & Other Facilities [Member]
Concentration Risk, Percentage	[1]	24.20%	24.16%	26.75%
Bon Secours DePaul and Maryview Medical Center [Member]
Concentration Risk, Percentage	[2]	9.03%	11.72%	6.51%
[1]	This group of facilities individually do not aggregate to more than 10% of total Company product sales. They are serviced by the same physician group, one of whom is our Medical Director.
[2]	These two facilities are part of the same network and currently share one physician who performs procedures in both facilities. Individually, these facilities would not meet the 10% criteria, however, in aggregate, they do.

Concentrations of Credit and 72

Concentrations of Credit and Other Risks (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Product Information [Line Items]
Inventory Write-down			$ 72,200	$ 0	$ 0
GliaSite® RTS [Member]
Product Information [Line Items]
Inventory Write-down	$ 72,200	$ 72,200

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Related Party Transaction [Line Items]
Maintenance costs	$ 0	$ 0	$ 3,720
Software implementation costs	6,000	12,000	12,000
Amount accrued for payment	0	2,000
Website modifications and maintenance	6,000	$ 12,000	$ 12,000
GO Intellectual Capital LLC [Member]
Related Party Transaction [Line Items]
Payments For Go To Market Services	$ 105,659

Quarterly Financial Data (Detai

Quarterly Financial Data (Details) - USD ($)	3 Months Ended																12 Months Ended
	Jun. 30, 2016		Mar. 31, 2016		Dec. 31, 2015		Sep. 30, 2015		Jun. 30, 2015		Mar. 31, 2015		Dec. 31, 2014		Sep. 30, 2014		Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Net revenue	$ 1,120,245		$ 1,198,701		$ 1,189,008		$ 1,261,322		$ 1,340,744		$ 1,158,109		$ 1,065,585		$ 1,042,101		$ 4,769,276	$ 4,606,539	$ 4,219,158
Gross profit/(loss)	(47,520)		66,304		26,911		83,459		204,962		55,197		(37,964)		(54,802)		129,154	167,393	(196,471)
Net loss	$ (1,184,813)		$ (1,195,297)		$ (1,311,588)		$ (1,019,110)		$ (1,034,682)		$ (953,553)		$ (906,954)		$ (785,862)		$ (4,710,808)	$ (3,681,051)	$ (5,959,122)
Net loss per share - basic and diluted	$ (0.02)	[1]	$ (0.02)	[1]	$ (0.02)	[1]	$ (0.02)	[1]	$ (0.02)	[1]	$ (0.02)	[1]	$ (0.02)	[1]	$ (0.01)	[1]	$ (0.09)	$ (0.07)	$ (0.16)
Shares used in basic and diluted per share calculation	55,010,619		55,022,668		55,013,553		55,012,901		54,900,828		54,883,551		54,883,445		54,868,053		55,014,922	54,882,350	42,675,158
[1]	Due to rounding, the total of the individual quarters and the year-end calculation on the Consolidated Statement of Operations may be different.